Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Yong Qi Quek
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Blk 1090 Lower Delta Road #06-08 Singapore Singapore 169201
- IPO Date
- Apr 10, 2025
- CIK
- 0001995704
- Website
- cuprina.com.sg
- Similar Companies
- Business
- Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, develops and commercializes innovative products for chronic wound management and operates in the health and beauty sectors; its core offerings include medical-grade sterile blowfly larvae bio-dressing products under the MEDIFLY brand for maggot debridement therapy, which non-surgically removes necrotic, sloughy or infected tissue from chronic wounds such as diabetic foot ulcers, venous leg ulcers and pressure ulcers; collagen wound care dressings comprising sponges, particles and hydrogels derived from bullfrog collagen sourced from abattoir waste; MEND Skin Restoration Balm, a hydrating product developed with Full Crimp Milk LLP for sports enthusiasts; Activ Labs range of energy and relief products targeted at athletes; and pipeline products utilizing medical leeches for wound treatment. The company serves healthcare providers and patients globally, with operations focused on Asia including Singapore and Hong Kong, and expansion into the US, GCC region and Southeast Asia; it targets markets for chronic wounds affecting millions, such as over 10.5 million Medicare beneficiaries in the US. Founded in 2019 and headquartered in Singapore, Cuprina Holdings (Cayman) Limited functions as a subsidiary of Cuprina Holding Pte. Ltd.. Recent developments include its initial public offering in 2025, which raised gross proceeds of $13.8 million through the sale of Class A ordinary shares on Nasdaq under the ticker CUPR, providing capital for R&D, market expansion, infrastructure upgrades and working capital; formation of a joint venture with Aiodine Laboratory Pte Ltd in November 2025 to develop, test and commercialize a novel iodine-based disinfectant solution for antiseptic wound care, disinfectants, home-use antiseptics and potential applications in personal care, oral hygiene and veterinary uses, with Cuprina responsible for global sales, marketing and distribution and clinical studies planned for 2026; appointment of Dr. Ronald A. Sherman, a pioneer in medical maggot therapy, as Medical and Scientific Director in September 2025, along with securing a license for his 2004 FDA clearance of Lucilia sericata Medical Maggots in the US; signing of a memorandum of understanding with Singapore Biowaste Solutions in October 2025 to integrate medical maggot therapy with biowaste solutions; and securing exclusive rights to a medical waste recycling technology for Southeast Asia in September 2025.
Cuprina Holdings Announces Completion of Reverse Stock Split and Requests a Hearing before the Nasdaq Hearings Panel to Maintain Listing
Cuprina Holdings announces 1-for-8 Share Consolidation
CUPR Investors Have Opportunity to Join Cuprina Holdings (Cayman) Limited Fraud Investigation with the Schall Law Firm
CUPR Investors Have Opportunity to Join Cuprina Holdings (Cayman) Limited Fraud Investigation with the Schall Law Firm
Rosen Law Firm Encourages Cuprina Holdings (Cayman) Ltd. Investors to Inquire About Securities Class Action Investigation – CUPR
Rosen Law Firm Encourages Cuprina Holdings (Cayman) Ltd. Investors to Inquire About Securities Class Action Investigation – CUPR
Super Copper Announces Investor Relations Agreement
Cuprina Holdings (Cayman) (NASDAQ:CUPR) Shares Down 2.4% – Should You Sell?
Financial Review: Petros Pharmaceuticals (NASDAQ:PTPI) & Cuprina Holdings (Cayman) (NASDAQ:CUPR)
Cuprina Holdings Announces Key Regulatory Milestone in Saudi Arabia and Strengthens Global Scientific Advisory Board
Cuprina Holdings (Cayman) Limited Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Cuprina Signs MOU with Singapore Biowaste Solutions to Integrate Medical Waste Management Technologies
Cuprina to Present Live, Answer Questions, at Skyline Signature Series™ on October 8th, 2025, at 11:00 AM ET
Cuprina Appoints Dr. Ronald Sherman, Leader in Maggot Debridement Therapy, as Medical and Scientific Director; Secures FDA-approved Medical Maggot License for U.S. Market
Cuprina Provides Update on Research Studies with Three Leading Education Institutes
Cuprina Completes Lab Able to Supply MEDIFLY Chronic Wound Therapy Across MENA Region, Secures Exclusive License to Market Medicinal Leeches in GCC Countries
Cuprina Holdings Announces Closing of Underwriter's Over-Allotment Option in Connection with Initial Public Offering
Cuprina Holdings Announces Completion, Receipt of Certification and License, for IVF Media Production Facility Built in Collaboration with Ferti-Craft Pte Ltd.
Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering
Cuprina Holdings (Cayman) Limited Announces Pricing of $12 million Initial Public Offering